Related Experiment Videos
Pharmacogenetics of controlled ovarian hyperstimulation
Francisco de Castro1, Francisco J Morón, Luis Montoro
1Hospital Universitario Príncipe de Asturias, Unidad de Reproducción Humana Asistida, Alcalá de Henares, Madrid, Spain.
Pharmacogenomics
|September 7, 2005
Summary
Genetic factors influence controlled ovarian hyperstimulation (COH) success in assisted reproductive techniques (ART). Understanding these genetic links can help predict and prevent cycle cancellation due to poor response or ovarian hyperstimulation syndrome (OHSS).
Area of Science:
- Reproductive Medicine
- Human Genetics
- Assisted Reproductive Technologies
Background:
- Controlled ovarian hyperstimulation (COH) is a cornerstone of assisted reproductive techniques (ART).
- Cycle cancellation in COH, due to poor response or ovarian hyperstimulation syndrome (OHSS), presents a significant clinical challenge.
- Genetic factors are increasingly suspected to play a role in COH outcomes.
Purpose of the Study:
- To review the evidence for genetic factors influencing COH outcomes.
- To genetically dissect the extreme phenotypes of COH: poor response and OHSS.
- To explore the potential for developing predictive genetic panels for COH management.
Main Methods:
- Literature review focusing on genetic associations with COH.
- Analysis of studies investigating single nucleotide polymorphisms (SNPs) and their relation to COH phenotypes.
- Synthesis of current understanding regarding genetic dissection of COH outcomes.
Main Results:
- Evidence suggests associations between single nucleotide polymorphisms (SNPs) and COH outcomes.
- Genetic variations may explain individual responses to COH, including poor response and hypersensitivity leading to OHSS.
- Ongoing research aims to identify specific genetic markers for predicting COH success.
Conclusions:
- Genetic factors are integral to understanding and managing COH outcomes in ART.
- Identifying genetic predispositions can aid in personalizing COH protocols.
- Development of predictive genetic panels holds promise for improving ART success rates and patient care.